Abstract:Escherichia coli is one of the most common strains of extended-spectrum β-lactam (ESBL)-producing bacteria, and the prevention and treatment of ESBL-producing E. coli infections is an ongoing challenge. The clinical characteristics and outcomes of ESBL-producing E. coli bacteremia in non-transplant patients remain to be elucidated. This retrospective study included 491 non-transplant patients with E. coli bloodstream infections (BSIs) from January 2013 to December 2016 and was conducted to investigate the risk factors, clinical features, and outcomes of these infections. Of the 491 E. coli BSI patients, 57.6% suffered from infections with ESBL-producing strains. A multivariate analysis showed that urinary tract infection, prior use of cephalosporin, and treatment with β-lactam-β-lactamase inhibitor (BLBLI) combination antibiotics were independent risk factors for the development of ESBL-producing E. coli BSIs. The overall mortality rate in E. coli BSI patients was 14.46%, and there was no significant difference in the 28 day mortality rate between ESBL-producing E. coli and non-ESBL-producing E. coli BSI patients (14.8% vs. 14.0%, respectively; P = 0.953). Similarly, there was no difference between the community-acquired infection group and the nosocomial infection group. Hepatobiliary disease, carbapenem exposure, high APACHE II score, and hypoproteinemia were independent risk factors for death in E. coli BSI patients. Multivariate analysis showed that hypoproteinemia and severe disease were independent risk factors for death from ESBL-producing E. coli BSIs. Furthermore, there was no significant difference in the 28 day mortality between patients with ESBL-producing E. coli BSIs treated with carbapenem monotherapy versus those treated with BLBLI combination antibiotics (12.8% vs. 17.9%, respectively; P = 0.384). Prior use of cephalosporin or BLBLI combination antibiotics increased the risk ratio for ESBL-producing E. coli infection. Hypoproteinemia and severe disease are independent risk factors for death in patients with E. coli BSIs. There was no significant difference in the 28 day prognosis of patients with ESBL-producing E. coli and those with non-ESBL-producing E. coli BSIs. These data do not support the conclusion that carbapenems might be more effective than BLBLI antibiotics for treatment of patients with BSIs caused by ESBL-producing E. coli.

Comparison of Empirical Therapy with Cefoperazone/sulbactam or a Carbapenem for Bloodstream Infections Due to ESBL-producing Enterobacteriaceae.

Comparison of the Relative Efficacy of Β-Lactam/β-lactamase Inhibitors and Carbapenems in the Treatment of Complicated Urinary Tract Infections Caused by Ceftriaxone-Non-susceptible Enterobacterales: a Multicentre Retrospective Observational Cohort Study.

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae

Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis

Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes

Bloodstream Infections Due To Carbapenem-Resistantklebsiella Pneumoniae: A Single-Center Retrospective Study On Risk Factors And Therapy Options

A Real-World Study Comparing Various Antimicrobial Regimens for Bloodstream Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli in a Tertiary Hospital, Shanghai, China, from 2010 to 2017

Comparison of Tigecycline or Cefoperazone/Sulbactam Therapy for Bloodstream Infection Due to Carbapenem-resistant Acinetobacter Baumannii

Pharmacoeconomics on Treatment of Gram-Negative Bacteria Infections with Cefoperazone-Sulbactam, Imipenem-Cilastatin, and Piperacillin-Tazobactam

Piperacillin/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis

Risk Factors and Outcomes in Non-Transplant Patients with Extended-Spectrum Beta-Lactamase-producing Escherichia Coli Bacteremia: a Retrospective Study from 2013 to 2016

[The Efficacy and Safety of Different Antimicrobial Regimens in Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections].

Cefepime, Not Piperacillin/Tazobactam Use, for Empirical Treatment of Bloodstream Infections Caused by Enterobacter Spp.: Results from a Population Pharmacokinetic/pharmacodynamic Analysis.

Clinical And Economic Outcomes Associated With Community-Acquired Intra-Abdominal Infections Caused By Extended Spectrum Beta-Lactamase (Esbl) Producing Bacteria In China

[Patients of Escherichia Coli Bloodstream Infection: Analysis of Antibiotic Resistance and Predictors of Mortality].

Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant <i>Enterobacterales</i>

Effectiveness of short treatment duration for carbapenemase-producing Enterobacterales in bloodstream-infections: A retrospective cohort study

Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study.

A Retrospective Analysis of Risk Factors and Outcomes in Patients with Extended-Spectrum Beta-Lactamase-producing Escherichia Coli Bloodstream Infections.

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.